MDMA-Assisted Therapy
MDMA-Assisted Therapy is a psychedelic-assisted treatment developed through MAPS, the Multidisciplinary Association for Psychedelic Studies, with Michael Mithoefer as principal author of its treatment manual and lead investigator of the first trial in 2010; the 2021 date marks its Phase 3 results, not its origin. Its core mechanism: mDMA reduces the fear response and increases trust and empathy, making it possible to stay with trauma material inside the therapeutic relationship. This catalogue links it to PTSD and complex trauma, typically in individual (co-therapist) format, short (3 sessions).
Related condition topics
These links support exploration. They do not establish that MDMA-Assisted Therapy is effective or recommended for each condition.
How MDMA-Assisted Therapy works
MDMA reduces the fear response and increases trust and empathy, making it possible to stay with trauma material inside the therapeutic relationship
Ontology
PTSD maintained by overwhelming fear that prevents therapeutic engagement; MDMA lowers this barrier pharmacologically
Therapeutic Voice
"You're safe here. If something difficult comes up, you can move toward it. You don't have to do this alone."
View of the Person
A traumatized being whose fear barriers to therapeutic engagement can be pharmacologically lowered to enable processing
Epistemology
Evidence
4 source checks available
An overall effectiveness assessment has not been completed. This describes the state of our review, not whether the approach works.
Guidelines and official sources (4)
3 clinical guideline checks · 1 regulatory source check
Read the recommendation and its scope. A source may discuss an approach without recommending it.
- NDA 215455: midomafetamine complete response letter
Not a treatment recommendation
The letter verifies the 2024 nonapproval decision and identifies safety reporting, durability and bias concerns. Psychotherapy-contribution questions appear separately as additional comments.
Scope: Midomafetamine application NDA 215455 for PTSD
- Clinical Practice Guideline for Management of PTSD and Acute Stress Disorder
Insufficient evidence for or against
VA/DoD finds insufficient evidence for or against MDMA-assisted psychotherapy. The guideline’s evidence cutoff precedes later trials and regulatory decisions.
Scope: MDMA-assisted psychotherapy for adults with PTSD; evidence reviewed through May 2022.
- Management of Major Depressive Disorder
Recommendation against the stated use
VA/DoD strongly recommends against MDMA for MDD outside research. This 2022 guideline used evidence through January 2021; it does not assess later trials or every diagnosis.
Scope: MDMA for MDD outside research settings.
- Clinical Practice Guideline for the Treatment of Posttraumatic Stress Disorder in Adults
Insufficient evidence for or against
APA finds insufficient evidence for or against this intervention in the reviewed comparisons.
Scope: Adults with PTSD; MDMA-assisted psychotherapy versus the inactive or low-dose active comparators reviewed.
Recorded material under review
The existing notes below are retained separately from assessment records. These recorded claims await source checking, including study design, recommendations and numerical estimates.
Phase 3 trials (Mitchell et al., 2021, 2023)
Phase 3 data analyzed
Phase 3 showed large effects. FDA advisory committee voted against approval Aug 2024: functional unblinding and data concerns. Regulatory status unresolved.
Training and certification
Not FDA-approved (2025). MAPS Training for research/expanded access. Co-therapist model
MAPS training program; regulatory evolving
Core: 80-120 hrs + supervised sessions
$5K-10K
Find a trained therapist
Equity & Cultural Adaptations
Clinical cautions and blind spots
Assessment and precautions
Recorded cautions include cardiovascular conditions (uncontrolled hypertension and arrhythmias), hepatic impairment, current MAOI use (serotonin toxicity risk), active psychosis or psychotic spectrum disorders, seizure disorders, and pregnancy. Current SSRI treatment requires protocol-specific medication review: some SSRIs can alter MDMA's effects, but this does not establish that the combination is safe. Any medication change must be individualized with the prescribing clinician, including assessment of interactions and withdrawal or relapse risk.
Sources for the corrected statements:
Blind spots
FDA declined approval (2024); methodological concerns about unblinding; not currently legally available outside research
Philosophical roots
Mithoefer (inner healing intelligence); Rogers (organismic wisdom, given conditions); Buber (I-Thou enabled pharmacologically); trauma processing theory
Compared with other approaches
Controversies
FDA declined approval Aug 2024 (methodological concerns, unblinding, data integrity). Regulatory future uncertain. Separately, a former trial participant alleged inappropriate touch by two trial therapists during MDMA sessions; one of the therapists subsequently surrendered his license
The FDA declined to approve MDMA-assisted therapy for PTSD, citing trial design concerns, potential for bias, and safety risks. An advisory committee voted 9-2 against approval. Concerns included misconduct allegations during trials and blinding integrity questions.
MAPS expressed disappointment and stated it would work with FDA on a path forward. Supporters argue the FDA applied unusually stringent standards compared to other psychiatric medications.
Former trial participant Meaghan Buisson alleged inappropriate touch by therapists Richard Yensen and Donna Dryer during MDMA sessions. Allegations featured in the podcast Cover Story: Power Trip. Yensen’s license was subsequently surrendered.
MAPS acknowledged the allegations and published a Code of Ethics. Critics noted the Code’s promise to ‘never abandon a participant’ contradicted reported experiences of complainants.
Test Yourself
Why co-therapists?
Show answer
Two therapists provide containment during 6-8 hour sessions, model healthy relating.